Page 3 - Roche Group Genentech News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AC Immune Reports Positive Interim Results from Novel Phase 1b/2a Alzheimer s Vaccine Trial
Source:
Streetwise Reports  (2/11/21)
Shares of AC Immune SA traded 15% higher after the firm reported that interim results from the Phase 1b/2a Alzheimer s trial of its ACI-35.030 vaccine demonstrated generation of potent anti-phospho-Tau antibody responses in 100% of older patients with early Alzheimer s disease.
Switzerland-based clinical-stage biopharmaceutical firm AC Immune SA (ACIU:NASDAQ) today announced positive interim results from its ongoing Phase 1b/2a clinical trial evaluating its first-in-class anti-phospho-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer s disease (AD).
The company highlighted that the ACI-35.030 vaccination generated a potent antigen-specific antibody response against pTau in 100% of older patients with early AD, achieving antibody levels several orders of magnitude higher than pre-vacci ....

Andrea Pfeifer , Stephen Hytha , Eli Lilly , Roche Group Genentech , Streetwise Reports , Janssen Pharmaceuticals , Janssen Pharmaceuticals Inc , Tau Igg , Roche Group , Streetwise Report , ஆண்ட்ரியா பபெபேற் , எலி லில்லி , ரோச் குழு ஜெநிஂடெக் , ஜான்சன் மருந்துகள் , ஜான்சன் மருந்துகள் இன்க் , டா இக் , ரோச் குழு ,